LI vs NKTR · P/E 24, rev $16.06B vs rev $21.0M
Li Auto Inc (LI) versus Nektar Therapeutics (NKTR) — a side-by-side from cached financials, not a winner call.
Li Auto Inc (LI) is a auto manufacturers company listed on US.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Latest reported LI revenue for 2025-12-31 was $16.06B. Net income was $162.9M. Revenue was down 18.8% from 2024-12-31 to 2025-12-31. LI currently screens at market cap $26.62B and trailing P/E 24.2.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
LI currently screens at market cap $26.62B and trailing P/E 24.2. NKTR currently screens at market cap $307.2M.
Not investment advice. Open the LI and NKTR stock pages for the full models.
Not investment advice.